Catalyser

Transformer

Investir

dans l'industrie de la biotechnologie

Notre impact

L’impact de CTI va bien au-delà de la génération de rendements de premier ordre pour nos investisseurs – nos sociétés en portefeuille ont apporté des traitements vitaux à des milliers de patients et ont stimulé la croissance de l’écosystème local de l’innovation.

20+

Années d’activité

Plusieurs fonds levés

30+

Investissements

Thérapeutique et modalité agnostique

5

Approbations réglementaires

Plus de 10 essais cliniques

6

Entreprises créées

10+

Sorties

Taux de réussite de 40 %

100s

Emplois créés

Qui sommes-nous

Plus qu’un investisseur – nous sommes un « Company Builder » qui catalyse des idées et des actifs naissants pour en faire des entreprises biotechnologiques investissables, évolutives et commercialisables. Les avantages de CTI sont

Thèse de Création de Valeur Durable

Les acquéreurs paient une prime pour accéder à des actifs biotechnologiques clés et compenser les pertes liées aux brevets

Stratégie d'investissement différenciée

Approche à double volet axée à la fois sur la création de valeur à long terme et sur l’accélération du calendrier de sortie

Gestion de portefeuille ciblée

Orienter les investissements vers une sortie significative en s’appuyant sur une expertise sectorielle approfondie et un réseau étendu

Rencontrez notre équipe

Une équipe expérimentée, dotée d’un bilan éprouvé et de compétences complémentaires, capable d’accompagner les investissements biotechnologiques depuis leur création jusqu’aux étapes clés de leur  développment.

Sociétés du portefeuille

Entreprises actives

Voir le portefeuille
Ability Pharma has a first-in-class autophagy driven treatment for metastatic pancreatic cancer, one of the deadliest cancers, and its interim blinded Phase 2b data suggested a significant improvement over the current standard of care.
Aeovian is a clinical-stage biotherapeutics company developing mTORC1-specific inhibitors.
DalCor was created based on a Phase 3-ready precision cardiology asset from the Montreal Heart Institute, a leader in cardiology research.
Domain’s unique platform produced potential best-in-class assets against valuable GPCR targets, its lead assets demonstrated best-in-class data in the pre-clinical setting.
enGene’s lead program has competitive efficacy and safety data and a distinct delivery advantage, positioning it as the go-to treatment of choice for urologists.
Epitopea had a novel approach to identify tumor specific antigens that are highly immunogenic and shared across patients to enable true off-the-shelf cancer vaccines.
Find Therapeutics' platform that could design differentiated peptide-based therapies for intramembrane targets and its lead asset showed promising pre-clinical data.
Glycomine has a substrate replacement therapy that directly bypass the mutated enzyme in patients with PMM2-CDG; it is not only a first-in-class treatment but also the only disease modifying treatment.
Oligon is a pre-clinical biotech company developing the SeekR™ platform to enable self-delivering siRNA therapies beyond the liver.
Phenomic AI’s platform integrates one of the world's largest single-cell RNA (scRNA) datasets from human tissues, enabling the analysis of complex cell-cell interactions within multi-cell systems.
Profound’s MRI guided ablation not only improves survival outcome but is also significantly less invasive compared to traditional approach.
Thryv has a first-in-class treatment for a rare pediatric cardiology disease called Long QT Syndrome that demonstrated strong efficacy signal in its Phase 2a study.

Sociétés en voie de défaire

Voir le portefeuille
Amolyt’s parathyroid receptor agonist is specifically designed to bind to the calcium channel in the kidney and not in the bone, thus restoring serum calcium level without affecting deteriorating bone.
Enobia had a first-in-class disease modifying treatment for a rare and life-threatening pediatric disease called hypophosphatasia.
GLyPhama was created based on a deprioritized and highly de-risked asset from Ferring with best-in-class potential for treating short bowl syndrome.
Medicago’s plant-based platform had significant speed and cost advantages compared to traditional protein and vaccine production methods.
TargeGen's lead asset was being developed for myelofibrosis and polycythemia vera, conditions without approved therapies at the time.
Vaxcyte had the best-in-class pneumococcal conjugate vaccine (PCV) for pneumococcal disease which would make Vaxcyte and attractive target for current PCV marketers.
VectivBio's GLP-2 analog had significant competitive advantages against other GLP-2 assets, and can be used in a more broad short-bowl syndrome population.
Visterra had a proprietary technology platform, Hierotope, to design precision biologics that specifically bind to and modulate key disease targets.
Zymeworks had two innovative rationale design platforms – Azymetric and Zymelink, for rationale design of antibody-based treatments.